Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2016; 06(04): 91-102
DOI: 10.4103/2231-0770.191445
REVIEW ARTICLE

Does endothelial dysfunction correlate with endocrinal abnormalities in patients with polycystic ovary syndrome?

Rajani Dube
Department of Obstetrics and Gynaecology, Ras al-Khaimah Medical and Health Sciences University, Al Qusaidat, Ras al-Khaimah, United Arab Emirates
› Author Affiliations
Financial support and sponsorship Nil.
› Further Information
Also available at
 PDF Download Permissions and Reprints

Abstract

To study and critically analyze the published evidence on correlation of hormonal abnormalities and endothelial dysfunction (ED) in polycystic ovary syndrome (PCOS) through a systematic review. The databases including MEDLINE, PubMed, Up-To-Date, and Science Direct were searched using Medical subject handling terms and free text term keywords such as endocrine abnormalities in PCOS, ED assessment in PCOS, ED in combination with insulin resistance (IR), hyperandrogenism (HA), increased free testosterone, free androgen index (FAI), gonadotrophin levels, luteinizing hormone (LH), prolactin, estrogen, adipocytokines to search trials, and observational studies published from January 1987 to September 2015. Authors of original studies were contacted for additional data when necessary. PCOS increases the risk of cardiovascular disease in women. ED, which is a reliable indicator of cardiovascular risk in general population, is seen in most (but not all) women with PCOS. IR, seen in 70% patients with PCOS, is associated with ED in these women, but patients can have normal endothelial function even in the presence of IR. Free testosterone and FAI are consistently associated with ED, but endothelial function can be normal despite HA. Estradiol (not estrone) appears to be protective against ED though estrone is the predominant estrogen produced in PCOS. Increased levels of adipocytokines (visfatin) are promising in predicting ED and cardiovascular risk. However, more studies are required focusing on direct correlation of levels of prolactin, LH, estrone, and visfatin with ED in PCOS.

Keywords

Adipocyte-secreted hormones - endothelial dysfunction - estrogen - follicular stimulating hormone - hyperandrogenism - insulin resistance - luteinizing hormone - polycystic ovary syndrome - prolactin


Publication History

Article published online:
09 August 2021

© 2016. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-97.
  • 2 March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544-51.
  • 3 Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clin Endocrinol (Oxf) 2013;78:438-46.
  • 4 Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. Current Issues in Endocrinology and Metabolism. Boston: Blackwell Scientific; 1992. p. 377-84.
  • 5 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  • 6 Moran LJ, Cameron JD, Strauss BJ, Teede HJ. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod 2011;26:2192-9.
  • 7 Koiou E, Tziomalos K, Katsikis I, Dinas K, Tsourdi EA, Kandaraki EA, et al. Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones (Athens) 2012;11:77-85.
  • 8 Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 2007;67:735-42.
  • 9 Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49.
  • 10 Butt M, Dwivedi G, Blann A, Khair O, Lip GY. Endothelial dysfunction: Methods of assessment & implications for cardiovascular diseases. Curr Pharm Des 2010;16:3442-54.
  • 11 Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.
  • 12 Sorensen MB, Franks S, Robertson C, Pennell DJ, Collins P. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin Endocrinol (Oxf) 2006;65:655-9.
  • 13 Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, et al. Ovulation induction in polycystic ovary syndrome. J Obstet Gynaecol Can 2010;32:495-502.
  • 14 American College of Obstetricians and Gynecologists. Polycystic Ovary Syndrome. ACOG Practice Bulletin No. 108. Washington, DC: American College of Obstetricians and Gynecologists; 2009.
  • 15 Royal College of Obstetricians and Gynaecologists. Long-term consequences of polycystic ovary syndrome. Green-top Guideline No. 33. London, UK: Royal College of Obstetricians and Gynaecologists; 2007.
  • 16 Beckmann CR, Ling FW, Herbert WN, Smith RP, Casanova R, Chuang A, et al. From hirsutism and virilization. In: Beckmann CR, editor. Obstetrics and Gynecology. 7 th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014. p. 358.
  • 17 Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 2010;162:1093-9.
  • 18 Thierry van Dessel HJ, Lee PD, Faessen G, Fauser BC, Giudice LC. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3030-5.
  • 19 Freeman R, Pollack R, Rosenbloom E. Assessing impaired glucose tolerance and insulin resistance in polycystic ovarian syndrome with a muffin test: An alternative to the glucose tolerance test. Endocr Pract 2010;16:810-7.
  • 20 Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: Biobehavioral mechanisms and interventions. Fertil Steril 2010;94:1565-74.
  • 21 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-105.
  • 22 Indhavivadhana S, Wongwananuruk T, Rattanachaiyanont M, Techatraisak K, Leerasiri P, Tanmahasamut P, et al. Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thai 2010;93:653-60.
  • 23 Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6.
  • 24 Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003;80:255-8.
  • 25 Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 2009;58:714-21.
  • 26 Bhattacharya SM, Ghosh M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23:158-61.
  • 27 Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011;95:210-5.
  • 28 Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197-212.
  • 29 Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507.
  • 30 Franks S. Polycystic ovary syndrome: A changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
  • 31 Utiger RD. Insulin and the polycystic ovary syndrome. N Engl J Med 1996;335:657-8.
  • 32 Lanzone A, Fulghesu AM, Andreani CL, Apa R, Fortini A, Caruso A, et al. Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist. Hum Reprod 1990;5:143-9.
  • 33 Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;76:119-25.
  • 34 Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
  • 35 Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B-4B.
  • 36 Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990;81:1762-7.
  • 37 Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
  • 38 Flammer AJ, Lüscher TF. Human endothelial dysfunction: EDRFs. Pflugers Arch 2010;459:1005-13.
  • 39 Thomson RL, Brinkworth GD, Noakes M, Clifton PM, Norman RJ, Buckley JD. The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Hum Reprod 2012;27:2169-76.
  • 40 Ilie IR, Pepene CE, Duncea I, Ilie R. Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia. Cent Eur J Med 2008;3:257-70.
  • 41 Beltrame JF, Crea F, Camici P. Advances in coronary microvascular dysfunction. Heart Lung Circ 2009;18:19-27.
  • 42 Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40.
  • 43 Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623-40.
  • 44 Doyle M, Fuisz A, Kortright E, Biederman RW, Walsh EG, Martin ET, et al. The impact of myocardial flow reserve on the detection of coronary artery disease by perfusion imaging methods: An NHLBI WISE study. J Cardiovasc Magn Reson 2003;5:475-85.
  • 45 Utz W, Jordan J, Niendorf T, Stoffels M, Luft FC, Dietz R, et al. Blood oxygen level-dependent MRI of tissue oxygenation: Relation to endothelium-dependent and endothelium-independent blood flow changes. Arterioscler Thromb Vasc Biol 2005;25:1408-13.
  • 46 Leung DY, Leung M. Non-invasive/invasive imaging: Significance and assessment of coronary microvascular dysfunction. Heart 2011;97:587-95.
  • 47 Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrage D, et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235-41.
  • 48 Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr., Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-41.
  • 49 Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998;82:1535-9, A7-8.
  • 50 Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003;146:168-74.
  • 51 Lavie P, Schnall RP, Sheffy J, Shlitner A. Peripheral vasoconstriction during REM sleep detected by a new plethysmographic method. Nat Med 2000;6:606.
  • 52 Debbabi H, Bonnin P, Ducluzeau PH, Lefthériotis G, Levy BI. Noninvasive assessment of endothelial function in the skin microcirculation. Am J Hypertens 2010;23:541-6.
  • 53 Idei N, Ukawa T, Kajikawa M, Iwamoto Y, Fujimura N, Maruhashi T, et al. A novel noninvasive and simple method for assessment of endothelial function: Enclosed zone flow-mediated vasodilation (ezFMD) using an oscillation amplitude measurement. Atherosclerosis 2013;229:324-30.
  • 54 Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
  • 55 Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996;78:1210-4.
  • 56 Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995;26:327-31.
  • 57 Parker BA, Tschakovsky ME, Augeri AL, Polk DM, Thompson PD, Kiernan FJ. Heterogenous vasodilator pathways underlie flow-mediated dilation in men and women. Am J Physiol Heart Circ Physiol 2011;301:H1118-26.
  • 58 Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
  • 59 Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17.
  • 60 Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: The role of flow-mediated dilatation. Eur Heart J 2010;31:2854-61.
  • 61 Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:H2-12.
  • 62 Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. Hypertension 2010;55:1075-85.
  • 63 Sansores RH, Abboud RT, Kennell C, Haynes N. The effect of menstruation on the pulmonary carbon monoxide diffusing capacity. Am J Respir Crit Care Med 1995;152:381-4.
  • 64 Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
  • 65 Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008;117:2262-9.
  • 66 Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994;93:50-5.
  • 67 Charakida M, Donald AE, Terese M, Leary S, Halcox JP, Ness A, et al. Endothelial dysfunction in childhood infection. Circulation 2005;111:1660-5.
  • 68 Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: From research into clinical practice. Circulation 2012;126:753-67.
  • 69 Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-5.
  • 70 Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:749-56.
  • 71 Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088-95.
  • 72 Orio F Jr., Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072-6.
  • 73 Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, et al. Endothelial dysfunction in PCOS: Role of obesity and adipose hormones. Am J Med 2006;119:356.e1-6.
  • 74 Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-7.
  • 75 Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-31.
  • 76 Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005;116:207-14.
  • 77 Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008;196:958-65.
  • 78 Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82-90.
  • 79 Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008;200:336-44.
  • 80 Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond) 2009;116:761-70.
  • 81 Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009;204:509-14.
  • 82 Mohamadin AM, Habib FA, Al-Saggaf AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. Ann Saudi Med 2010;30:278-83.
  • 83 Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: The effects of medical therapy. Fertil Steril 2010;93:184-91.
  • 84 Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005;58:151-4.
  • 85 Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.
  • 86 Jezovnik MK, Jensterle Sever M, Janez A, Pfeifer M, Spirkoska A, Kravos NA, et al. Comparison of different methods investigating functional and morphological markers of early atherogenesis in obese women with polycystic ovary syndrome. Int Angiol 2015;35:446-54.
  • 87 Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007;30:1029-34.
  • 88 Empen K, Lorbeer R, Dörr M, Haring R, Nauck M, Gläser S, et al. Association of testosterone levels with endothelial function in men: Results from a population-based study. Arterioscler Thromb Vasc Biol 2012;32:481-6.
  • 89 Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011;6:1617-25.
  • 90 Lopes RA, Neves KB, Carneiro FS, Tostes RC. Testosterone and vascular function in aging. Front Physiol 2012;3:89.
  • 91 Brinkworth GD, Noakes M, Moran LJ, Norman R, Clifton PM. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome. BJOG 2006;113:1308-14.
  • 92 Sprung VS, Jones H, Pugh CJ, Aziz NF, Daousi C, Kemp GJ, et al. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond) 2014;126:67-74.
  • 93 Studen KB, Sebestjen M, Pfeifer M, Prezelj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:389-95.
  • 94 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
  • 95 Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
  • 96 Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:597-604.
  • 97 Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012;7:207-15.
  • 98 Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592-6.
  • 99 Karakas SE, Kim K, Duleba AJ. Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome. Diabetes Care 2010;33:887-93.
  • 100 Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2014;30:367-71.
  • 101 Victor VM, Rovira-Llopis S, Bañuls C, Diaz-Morales N, Lopez-Domenech S, Escribano-López I, et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis 2015;242:167-73.
  • 102 Merhi Z, Mcgee EA, Buyuk E. Role of advanced glycation end-products in obesity-related ovarian dysfunction. Minerva Endocrinol 2014;39:167-74.
  • 103 Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008;69:634-41.
  • 104 Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome? Metabolism 2015;64:1564-73.
  • 105 Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581-9.
  • 106 Lambert EA, Teede H, Sari CI, Jona E, Shorakae S, Woodington K, et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clin Endocrinol (Oxf) 2015;83:812-9.
  • 107 Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1851-6.
  • 108 Yavuz Taslipinar M, Kiliç N, Bayraktar N, Güler I, Gülcan Kurt Y, Göktas T, et al. Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. Turk J Med Sci 2014;44:787-91.
  • 109 Rhee SS, Pearce EN. Update: Systemic diseases and the cardiovascular system (II). The endocrine system and the heart: A review. Rev Esp Cardiol 2011;64:220-31.
  • 110 Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.
  • 111 Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
  • 112 Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
  • 113 Spritzer PM, Maturana MA, Farias A, Bittencourt PH Jr. Nitric oxide levels and hyperinsulinemia in postmenopausal women: Relationship with hormonal, metabolic and anthropometric measurements. Recent Research in Gynecological Endocrinology. New York: Parthenon; 2001. p. 185-8.
  • 114 Torgrimson BN, Meendering JR, Kaplan PF, Minson CT. Depot-medroxyprogesterone acetate and endothelial function before and after acute oral, vaginal, and transdermal estradiol treatment. Hypertension 2011;57:819-24.
  • 115 Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93 11 Suppl 1:S64-73.
  • 116 Ozegowska KE, Pawelczyk LA. The role of insulin and selected adipocytokines in patients with polycystic ovary syndrome (PCOS) - A literature review. Ginekol Pol 2015;86:300-4.